Literature DB >> 6043672

Nasopharyngeal carcinoma. Some observations on the clinical features and technique of examination.

G Choa.   

Abstract

Entities:  

Mesh：

Year:  1967        PMID： 6043672

Source DB:  PubMed          Journal:  Pac Med Surg


× No keyword cloud information.
  8 in total

1.  The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients.

Authors:  Li-Ting Liu; Qiu-Yan Chen; Lin-Quan Tang; Shan-Shan Guo; Ling Guo; Hao-Yuan Mo; Ming-Yuan Chen; Chong Zhao; Xiang Guo; Chao-Nan Qian; Mu-Sheng Zeng; Jin-Xin Bei; Jing Tan; Shuai Chen; Ming-Huang Hong; Jian-Yong Shao; Ying Sun; Jun Ma; Hai-Qiang Mai
Journal:  Cancer Res Treat       Date:  2017-04-05       Impact factor: 4.679

2.  Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.

Authors:  Xue-Song Sun; Wen-Hui Chen; Sai-Lan Liu; Yu-Jing Liang; Qiu-Yan Chen; Shan-Shan Guo; Yue-Feng Wen; Li-Ting Liu; Hao-Jun Xie; Qing-Nan Tang; Xiao-Yun Li; Jin-Jie Yan; Hai-Qiang Mai; Lin-Quan Tang
Journal:  Cancer Med       Date:  2019-06-18       Impact factor: 4.452

3.  Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.

Authors:  Di-Han Liu; Xiao-Yu Zhou; You-Guang Pan; Si Chen; Zheng-Hao Ye; Gang-Dong Chen
Journal:  Cancer Med       Date:  2019-12-20       Impact factor: 4.452

4.  SDF2L1 Inhibits Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma.

Authors:  Liqian Zhang; Zunni Zhang; Liuqun Qin; Xiang Shi; Qisheng Su; Wuning Mo
Journal:  Biomed Res Int       Date:  2020-08-07       Impact factor: 3.411

5.  Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [18 F]-fluorodeoxyglucose positron emission tomography.

Authors:  Hao-Jun Xie; Yi-Fei Yu; Xue-Song Sun; Guo-Dong Jia; Dong-Hua Luo; Rui Sun; Li-Ting Liu; Shan-Shan Guo; Sai-Lan Liu; Qiu-Yan Chen; Lin-Quan Tang; Hai-Qiang Mai
Journal:  Cancer Med       Date:  2020-10-09       Impact factor: 4.452

6.  Efficiency of high cumulative cisplatin dose in high- and low-risk patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Yu-Ting Jiang; Kai-Hua Chen; Jie Yang; Zhong-Guo Liang; Ling Li; Song Qu; Xiao-Dong Zhu
Journal:  Cancer Med       Date:  2021-12-03       Impact factor: 4.452

7.  Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.

Authors:  Sai-Lan Liu; Xue-Song Sun; Hao-Jun Xie; Qiu-Yan Chen; Huan-Xin Lin; Hu Liang; Yu-Jing Liang; Xiao-Yun Li; Jin-Jie Yan; Chao Lin; Zhen-Chong Yang; Shan-Shan Guo; Li-Ting Liu; Qing-Nan Tang; Yu-Yun Du; Lin-Quan Tang; Ling Guo; Hai-Qiang Mai
Journal:  BMC Cancer       Date:  2020-02-03       Impact factor: 4.430

8.  Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.

Authors:  Qiu-Yan Chen; Shao-Yan Guo; Lin-Quan Tang; Tong-Yu Lu; Bo-Lin Chen; Qi-Yu Zhong; Meng-Sha Zou; Qing-Nan Tang; Wen-Hui Chen; Shan-Shan Guo; Li-Ting Liu; Yang Li; Ling Guo; Hao-Yuan Mo; Rui Sun; Dong-Hua Luo; Chong Zhao; Ka-Jia Cao; Chao-Nan Qian; Xiang Guo; Mu-Sheng Zeng; Hai-Qiang Mai
Journal:  Cancer Res Treat       Date:  2017-09-13       Impact factor: 4.679
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.